GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vitrolife AB (LTS:0YAY) » Definitions » Cyclically Adjusted PS Ratio

Vitrolife AB (LTS:0YAY) Cyclically Adjusted PS Ratio : 12.45 (As of Jan. 18, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Vitrolife AB Cyclically Adjusted PS Ratio?

As of today (2025-01-18), Vitrolife AB's current share price is kr207.25. Vitrolife AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was kr16.64. Vitrolife AB's Cyclically Adjusted PS Ratio for today is 12.45.

The historical rank and industry rank for Vitrolife AB's Cyclically Adjusted PS Ratio or its related term are showing as below:

LTS:0YAY' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 8.74   Med: 24.62   Max: 62.6
Current: 11.99

During the past years, Vitrolife AB's highest Cyclically Adjusted PS Ratio was 62.60. The lowest was 8.74. And the median was 24.62.

LTS:0YAY's Cyclically Adjusted PS Ratio is ranked worse than
89.91% of 436 companies
in the Medical Devices & Instruments industry
Industry Median: 2.285 vs LTS:0YAY: 11.99

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vitrolife AB's adjusted revenue per share data for the three months ended in Sep. 2024 was kr6.395. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is kr16.64 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vitrolife AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Vitrolife AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vitrolife AB Cyclically Adjusted PS Ratio Chart

Vitrolife AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.65 27.00 59.40 14.74 12.79

Vitrolife AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.12 12.79 12.78 10.69 15.27

Competitive Comparison of Vitrolife AB's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, Vitrolife AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vitrolife AB's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vitrolife AB's Cyclically Adjusted PS Ratio falls into.



Vitrolife AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Vitrolife AB's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=207.25/16.64
=12.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitrolife AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Vitrolife AB's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=6.395/132.3043*132.3043
=6.395

Current CPI (Sep. 2024) = 132.3043.

Vitrolife AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 1.261 100.225 1.665
201503 1.496 99.950 1.980
201506 1.696 99.995 2.244
201509 1.629 100.228 2.150
201512 1.833 100.276 2.418
201603 1.723 100.751 2.263
201606 1.914 101.019 2.507
201609 1.939 101.138 2.537
201612 2.311 102.022 2.997
201703 2.249 102.022 2.917
201706 2.629 102.752 3.385
201709 2.265 103.279 2.902
201712 2.495 103.793 3.180
201803 2.432 103.962 3.095
201806 2.609 104.875 3.291
201809 2.616 105.679 3.275
201812 2.949 105.912 3.684
201903 2.874 105.886 3.591
201906 3.507 106.742 4.347
201909 3.482 107.214 4.297
201912 3.772 107.766 4.631
202003 3.076 106.563 3.819
202006 1.927 107.498 2.372
202009 2.949 107.635 3.625
202012 3.523 108.296 4.304
202103 3.491 108.360 4.262
202106 3.519 108.928 4.274
202109 3.461 110.338 4.150
202112 4.142 112.486 4.872
202203 5.554 114.825 6.399
202206 6.123 118.384 6.843
202209 5.894 122.296 6.376
202212 6.315 126.365 6.612
202303 6.307 127.042 6.568
202306 6.684 129.407 6.834
202309 6.263 130.224 6.363
202312 6.684 131.912 6.704
202403 6.211 132.205 6.216
202406 6.950 132.716 6.928
202409 6.395 132.304 6.395

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vitrolife AB  (LTS:0YAY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Vitrolife AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Vitrolife AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vitrolife AB Business Description

Traded in Other Exchanges
Address
Box 9080, Gothenburg, SWE, 400 92
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The group has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.

Vitrolife AB Headlines

No Headlines